Bear
it appears the inclusion profile is very good. Well under 40 Hdl and 75% of Acs prior events MI seems to give weight to Diamond Study data ? Also in Examine I believe the actual( rather than design ) data showed average or median time from prior Asc was 45 dayish ? Lastly what were the event rates in Callahan diabetic sub study of SparcL from their event tables ? I am purely guessing however Examine 8% plus say half the boost seen in Diamond of 2% gives us 10ish? That would give us something around 4.4 for on drug ? Why has no Analyst ever mentioned Diamond ?
